On October 25, Arthritis Consumer Experts (ACE) asked for your views on subsequent-entry biologics (SEBs). Health Canada defines SEBS as a “biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug.” Unlike generic medications, SEBs are not identical to their originator drugs. Since every biologic is made from living cells, even minor differences from the originator drug change the way a SEB acts in the body.
Today is the last day to complete this short survey to let us know how much you know about SEBs. Your feedback is vitally important to the work ACE conducts on behalf of the more than 456,000 Albertans living with arthritis.
Please be assured that all responses will remain anonymous and confidential. Personal information will not be collected as part of this survey.
In the annual meeting of the American College of Rheumatology, a researcher reported that a knee brace will help alleviate a patient’s osteoarthritis (OA) pains. David T. Felson, MD, of the University of Manchester in England and his colleagues found that patients with knee OA who wore a patellofemoral brace for 6 weeks experienced less pain and bone marrow lesions.
Bone marrow lesions represent regions of bone that display hyperintense signals on MRI and fibrosis, necrosis, and microfractures on histology. In an interview with MedPage Today, Felson said: “Bone marrow lesions have been shown to predict later cartilage loss and to correlate with pain and its severity, so may be a viable treatment target in OA.” Continue reading →
Every year, lupus experts and specialists volunteer their time and knowledge to help lupus patients at the Lupus Symposium. The symposium is presented by The BC Lupus Society.
The Lupus Symposium will be happening tomorrow, October 19, at St. Paul’s Hospital Lecture Theatre. Live video conferencing is available to people living in Abbotsford, Campbell River, Fort St. John, Kamloops, Kelowna, Nanaimo, Prince George, Terrace, Trail, Vernon and Victoria.
The 2013 Classification Criteria for Systemic Sclerosis helps patients identify and treat their systemic sclerosis (SSc) earlier. Systemic sclerosis is also known as scleroderma. This journal is developed by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) as an update to the 1980 version developed by the ACR.
In the new criteria, patients have systemic sclerosis if they have thickening of the fingers that extends from the proximal to the metacarpophalangeal joints. In addition or in lieu of, if a patient observes the following listed features, it may also indicate SSc.
In an article in “Rheumatology update”, co-author of the 2013 journal Dr. Frank van den Hoogen from the Netherlands said: “The 1980 ACR criteria were not sensitive enough to identify patients with early disease or limited cutaneous system sclerosis.” Calcinosis, flexion contractures of the fingers, tendon or bursal friction rubs, oesophageal dilatation and dysphagia were not included in the criteria because of its lack in sensitivity and specificity. The new criteria have a sensitivity of 0.91 and specificity of 0.92. In comparison, the 1980 ACR criteria had a sensitivity of 0.75 and specificity of 0.72.
If you observe these features in someone you know, please share this article with them so they may obtain the proper treatment.
If you live with rheumatoid arthritis, here is your chance to try out some of the latest physical activity trackers.
Physical activity trackers are small electronic devices that can be worn as a watch, clip or bracelet to monitor your physical activity. They have the potential to motivate and educate people with rheumatoid arthritis (RA) to become more active.
Physical activity has significant benefits for people with RA. By becoming physically active, people with RA decrease the risk of developing health complications, such as heart disease, diabetes and cancer. In turn, it drastically reduces their pain.
The Arthritis Research Centre of Canada is looking for participants to test two different physical activity trackers over a 4-week period.
The first tracker is called the FitBitTM Flex, a wrist-worn activity monitor that gives visual feedback on an individual’s physical activity. The tracker allows the participant to create personalized fitness goals and integrate their goals with social media such as Facebook and email.
Photo Credit: By Feelart/FreeDigitalPhotos.net
The second tracker is called the BodyMedia SenseWear™ Mini Armband. It is worn on the upper arm and tracks when the participant may be exercising, sleeping or just taking it easy during the day.
Participants must meet the following requirements:
Be 19 years or older.
Have been diagnosed with rheumatoid arthritis.
Have daily access to the internet.
Live in Metro Vancouver.
Participants will be asked to continue their normal level of physical activity throughout the study and will be offered a small gift honourarium as a thank you for their time. Courier costs for delivery and pick-up of the trackers will be covered.
If you are interested in taking part, please click here to fill out a short questionnaire to find out if you are eligible. The deadline for application is 11:59pm on Friday, October 11th 2013. For more information, please contact Charlene Yousefi, research coordinator at email@example.com or by phone at 604-207-4007.
Today is the last day to sign up to help other rheumatoid arthritis patients make decisions about their biologic treatments.
A team of Canada’s leading arthritis researchers and digital media scientists are developing an interactive web-based tool to help RA patients make informed decisions about biologic treatments with their doctor. The research team will be led by Linda Li, Associate Professor of the Department of Physical Therapy, University of British Columbia. This new patient decision aid, called ANSWER-2, will help RA patients decide:
If biologic therapy is the right choice for them; and,
Which biologic best meets their individual needs.
The Arthritis Research Centre of Canada is looking for participants to take part in a filmed interview about their real-life experiences in making decisions about using biologic therapy. The filmed interview will be featured in the ANSWER-2 decision aid tool and play a crucial role in conveying first-hand knowledge that can help others to decide what is most important in their decision-making process. Participants must meet the following requirements:
Have rheumatoid arthritis
Are comfortable speaking on camera
Are willing to share the reasons underlying their treatment decisions
Live in Vancouver, BC
Participants will be reimbursed for any travel expenses incurred, provided food and beverages, and awarded a small cash honourarium for their time and effort.
All the interviews are casually conducted and can be easily edited. Participants will be able to review and approve any footage they are featured in before it is published.
If you are interested in taking part, please click here to fill out a short questionnaire to find out if you are eligible. Do not miss out on this opportunity to share your perspective on biologic therapy to support others with rheumatoid arthritis! The deadline for application is tonight at 11:59pm. For more information, please contact Charlene Yousefi, research coordinator at firstname.lastname@example.org or by phone at 604-207-4007.